Ancrod (Viprinex/NM-V) for sudden sensorineural hearing loss

Thrombin-like snake-venom serine protease/defibrinogenating enzyme that cleaves fibrinogen. In the SSHL study, ancrod was evaluated as a parenteral treatment with fibrinogen concentration tracked as an outcome biomarker.

Verified as a real Nordmark-sponsored randomized, double-blind, placebo-controlled Phase 1/2 study of ancrod/Viprinex/NM-V in sudden sensorineural hearing loss. ClinicalTrials.gov lists Nordmark as the industry lead sponsor and ClinSupport as a collaborator, so the primary company has been corrected from ClinSupport to Nordmark. The trial completed in 2018 and has no posted ClinicalTrials.gov results; no current active hearing-loss development program was confirmed in this pass, so HearScape should treat it as a historical completed biologic/repurposed anticoagulant study rather than an active pipeline asset.